<div><strong>Eliza Charley suffers from Myalgic Encephalomyelitis (ME): a devastating, serious and disabling disease that has no known cure. </strong>
</div>
<div><br />
</div>
<div><strong>Since the last treatment:</strong> In 2022, thanks to the support of her community, Eliza underwent H.E.L.P. Apheresis treatment in Germany (a specialised blood filtering procedure, more below) that has shown promising results for ME patients. This treatment significantly improved her baseline, enabled her to sit up for longer periods, walk short distances, and enhanced her cognitive function.
</div>
<div><br />
</div>
<div><strong>Now, Eliza faces a new, urgent hurdle</strong>: after diligently avoiding Covid-19 for five years, Eliza recently contracted the virus, setting her health back and increasing her ME symptoms. After specialised consultations and renewed testing, Eliza has been prescribed an urgent round of Apheresis to tackle the severe impact of Covid-19.
</div>
<div>Apheresis treatment has long waiting lists and the clinic in Germany is one of only a handful of highly specialised clinics worldwide. It's crucial we act quickly.
</div>
<div><br />
</div>
<div><strong>Fundaising Goal</strong>
</div>
<div><br />
</div>
<div><strong>We aim to raise a minimum of $AUD 60,200 (approximately $USD 40,000 or €EUR 37,000) to cover the expected costs of the initial treatment, testing and some travel costs for her stay in Germany from her home in Italy. </strong>This will increase after the first test results come in.
</div>
<div><br />
</div>
<div>We ask for your generosity to help Eliza in this crucial time. Please note donation amounts are listed in Australian Dollars.
</div>
<div><br />
</div>
<div><em>For more on Eliza’s story, how the funds will be spent or to learn more about ME and H.E.L.P. Apheresis, read on below. </em>
</div>
<div><br />
</div>
<div><em>----------------------------</em>
</div>
<div><br />
</div>
<div><strong>Eliza's Story</strong>
</div>
<div><br />
</div>
<div>In 2009, Eliza caught a virus and never fully recovered. She contracted Myalgic Encephalomyelitis (ME), a serious and disabling disease, often first triggered by viral onset.
</div>
<div><br />
</div>
<div>In October 2020 she suffered a sudden major relapse following chronic infections and surgery. After rapid decline, by the end of 2021 she was often bedbound in a dark room, managing convulsions, immune surges, cellular crashes and a suite of debilitating impacts of this disease. She was almost completely housebound, required full time care, and could only have occasional outings with the aid of a wheelchair.
</div>
<div><br />
</div><img class="text-editor_textEditorImage__43_GE" alt="" media_type="3" src="https://d2g8igdw686xgo.cloudfront.net/84023077_1731365910458535_r." width="100%" />
<div><br />
</div>
<div>As a consequence of this disease-based disability and her partner David become her carer, their ability to work for income has been extremely limited.
</div>
<div><br />
</div>
<div><strong>Since Apheresis in 2022</strong>
</div>
<div><br />
</div>
<div>Since Eliza's first Apheresis treatment in Germany in 2022, her baseline has improved. Importantly, it halted her decline. Initially bedridden, by the end of 2022, Eliza was able to move around her home with the help of a wheelchair and walker, and her cognitive functions improved enough for her to engage in advocacy and enhance her Italian language skills.
</div>
<div><br />
</div>
<div><em>Eliza undergoing H.E.L.P Apheresis treatment in Germany in 2022</em>
</div>
<div><br />
</div><img class="text-editor_textEditorImage__43_GE" alt="" media_type="3" src="https://d2g8igdw686xgo.cloudfront.net/84023077_1731365959548386_r." width="100%" />
<div><br />
</div>
<div><br />
</div>
<div>Throughout 2023,<strong> </strong>despite fluctuations, her health continued to improve and her improved baseline enabled her to access additional medications, tests, and treatments, with specialist guidance in Italy, in Australia, and remotely from the UK. This regimen included in-clinic and at-home IV treatments. Ultimately, this allowed her to return to Australia in 2023 for the first time in two and a half years.
</div>
<div><br />
</div>
<div><em>With improvements to her baseline, Eliza was less house-bound and able to engage in occasional activities.</em>
</div>
<div><br />
</div><img class="text-editor_textEditorImage__43_GE" alt="" media_type="3" src="https://d2g8igdw686xgo.cloudfront.net/84023077_173136603018243_r." width="100%" />
<div><br />
</div>
<div><br />
</div>
<div>By 2024, Eliza had made slow and painful gains enough to start walking for up to 6 minutes once a week without worsening the disease, and being well enough to make a cup of tea whenever she wanted and drink it immediately without needing to rest after making it. She was also able to return to some semblance of engagement with life, albeit while still facing debilitating daily symptoms.
</div>
<div><br />
</div>
<div><em>By 2024, Eliza made slow gains and was able to engage with some social activities.</em>
</div>
<div><br />
</div><img class="text-editor_textEditorImage__43_GE" alt="" media_type="3" src="https://d2g8igdw686xgo.cloudfront.net/84023077_1731366160123476_r." width="100%" />
<div><br />
</div>
<div><br />
</div>
<div>In August and September this year, she was able to re-introduce a small amount of sporadic remote work, for the first time in four years. David and Eliza were so happy to finally be able to begin to make some plans for the future.
</div>
<div><br />
</div>
<div><strong>That hope ended with a COVID-19 infection in October 2024,</strong> which erased many of their hard won gains, with an indefinite threat of severe relapse unless she can access specific, appropriate and substantial treatment as soon as possible.
</div>
<div><br />
</div>
<div>----------------------------
</div>
<div><br />
</div>
<div><strong>What is Myalgic Encephalomyelitis (ME)?</strong>
</div>
<div><br />
</div>
<div>Myalgic Encephalomyelitis (ME) is “a chronic, complex, multi-system biological illness with often devastating consequences” (<a href="https://doctorswith.me/home/what-is-me/" target="_blank" rel="noreferrer noopener">Doctors with ME 2022</a> ). It is a multi-system, multi-organ disease supported by extensive biomedical research across three decades which has documented a complex picture of debilitating damage, including severely impacting the immune, nervous, musculoskeletal and cardiovascular systems, spine and spinal cord abnormalities, and, critically, cellular metabolism and energy production systems.
</div>
<div><br />
</div>
<div>In addition, there are a range of other conditions and diseases that can occur alongside ME (such as POTS, MCAS, and CCI which specialists have confirmed are all complicating factors in Eliza’s case).
</div>
<div><br />
</div>
<div><strong>A worse quality of life score than Cancer or MS</strong>
</div>
<div>ME patients have a worse quality of life score than many other serious illnesses including cancer, stroke, rheumatoid arthritis and MS. About 75% of sufferers are female. 25% of patients are housebound or bed bound. Severely affected patients can struggle to perform ALL activities of daily living, and extreme cases may even need tube feeding.
</div>
<div><br />
</div>
<div><strong>An extensive body of biomedical research </strong>
</div>
<div>Biomedical research across more than three decades into this disease has revealed a complex picture of debilitating damage. Repeatedly in studies, ME patients show abnormalities:
</div>
<div><br />
</div>
<ul>
<li>Abnormalities in the brain (including neuroinflammation, decreased cerebral blood flow, damage to grey matter, and brain lesions),
</li>
<li>In the immune system (abnormal cytokines and various immune cells, chronic bacterial infections, viral persistence and reactivations),
</li>
<li>In musculoskeletal and cardiovascular systems (hypercoagulation, hypoxia, endothelial damage, lactic acidosis),
</li>
<li>Spine and spinal cord abnormalities, and, critically, in
</li>
<li>Cellular metabolism (mitochondrial dysfunction, peroxisomal blockages, increased cell death).
</li>
</ul>
<div><br />
</div>
<div><em>Learn more about ME using the links and references included below.</em>
</div>
<div><br />
</div>
<div>---------------------
</div>
<div><br />
</div>
<div><strong>What is H.E.L.P. Apheresis?</strong>
</div>
<div><br />
</div>
<div>Heparin-induced extracorporeal LDL/fibrinogen precipitation (H.E.L.P.) Apheresis is an intensive blood-filtering treatment that sees a patient hooked up to a machine for several hours to have their blood filtered of certain abnormal and dangerous particles - removing viral debris, spike protein, inflammatory substances and microclots from the bloodstream, improving system-wide function.
</div>
<div><br />
</div>
<div>This is an existing therapy. Apheresis has been studied and used in range neurological and neurodegenerative diseases (Journal of Clinical Medicine 2020) , and is now being studied as a treatment in eligible patients with ME.
</div>
<div><br />
</div>
<div>Testing in 2022 at the German clinic, revealed Eliza’s blood to be positive for key markers including microclots, hyperactivated platelets, and endothelial damage.
</div>
<div><br />
</div>
<div><em>Fluorescence microscopy of Eliza’a blood after her recent COVID infection show that some of this altered function is now worse than ever. </em>
</div>
<div><br />
</div><img class="text-editor_textEditorImage__43_GE" alt="" media_type="3" src="https://d2g8igdw686xgo.cloudfront.net/84023077_1731366602608643_r." width="100%" />
<div><br />
</div>
<div>-----------------------
</div>
<div><br />
</div>
<div><strong>How your donation will help</strong>
</div>
<div><br />
</div>
<div>Your donation will help Eliza access a new round of Apheresis in Germany after COVID infection - including specialist consultations, treatments, tests, and travel costs.
</div>
<div><br />
</div>
<div>This Crowdfunding Campaign will help Eliza to access the following:
</div>
<ul>
<li>H.E.L.P. Apheresis Sessions in Bad Aibling, Germany (multiple required at €2100 each)
</li>
<li>Comprehensive pathology testing, including fluorescence microscopy, immune panels, co-infections and regular monitoring
</li>
<li>Additional prescribed treatments at the clinic including IV infusions
</li>
<li>Regular consultations with two world leading physicians
</li>
<li>Pharmacy costs and supplies
</li>
<li>Transport and accommodation for Eliza and David from Italy to Germany.
</li>
<li>Support for food and basic living costs with her and her caregiver unable to work during treatment periods
</li>
</ul>
<div><br />
</div>
<div><em>These are new costs, separate to the previously completed treatment and ongoing medication (average €1500 per month), and also excludes other travel to and medical treatment in Australia.</em>
</div>
<div><br />
</div>
<div>-----------------------
</div>
<div><br />
</div>
<div><strong>Can’t Help Financially? </strong>
</div>
<div><br />
</div>
<div>That’s ok, not everyone is in a position to assist financially. If you can’t, here’s some things you can do to show your support.
</div>
<div><br />
</div>
<div><strong>Get informed about ME.</strong>
</div>
<div>After many decades of published biomedical research and clinical trials for ME, a lot is known but few people know it. You can be part of the change to support patients by learning from reputable researchers and patient-informed sources (included below).
</div>
<div><br />
</div>
<div><strong>Share Eliza’s crowdfunding page via email or on social media </strong>
</div>
<div>Invite others in your network to join this opportunity to help Eliza and learn more about ME. If you’d like sample templates for email or social media posts and tiles please reach out using the contact form below.
</div>
<div><br />
</div>
<div><strong>Send a note of encouragement</strong>
</div>
<div>Share a note of support and encouragement to Eliza (@elizacharley) on Instagram or Whatsapp. As you can imagine she has very limited capacity while undergoing treatment so she is slow to respond, but it still means a lot.
</div>
<div><br />
</div>
<div><strong>Other questions</strong>
</div>
<div>Please reach out to Elilza’s sister Lucinda Hartley [email redacted] or David Shackelford [email redacted] if you have any questions about this crowdfunding campaign, or have other questions.
</div>
<div><br />
</div>
<div>-----------------------
</div>
<div><br />
</div>
<div><strong>Research and References</strong>
</div>
<div><br />
</div>
<div><strong>Medical guidance and research summaries:</strong>
</div>
<ul>
<li><a href="https://www.mayoclinicproceedings.org/article/S0025-6196(21)00513-9/fulltext" target="_blank" rel="noreferrer noopener">Myalgic Encephalomyelitis</a> / Chronic Fatigue Syndrome: Essentials of Diagnosis and Management. Mayo Clinic Proceedings (2021)
</li>
<li><a href="https://doctorswith.me/international-consensus-primer-for-medical-practitioners/" target="_blank" rel="noreferrer noopener">International Consensus Primer for Medical Practit</a> ioners - PDF available (2014)
</li>
<li><a href="https://doctorswith.me/nice-gp-update/" target="_blank" rel="noreferrer noopener">Summary Guidance for GPs</a> - Doctors with ME (2022)
</li>
<li><a href="https://polybio.org/project-type/me-cfs/" target="_blank" rel="noreferrer noopener">PolyBio Institute</a> (2024 List of current research areas)
</li>
</ul>
<div><br />
</div>
<div><strong>Helpful ME Websites: </strong>
</div>
<ul>
<li><a href="https://doctorswith.me/me-cfs-what-psychiatrists-need-to-know/" target="_blank" rel="noreferrer noopener">Doctors with ME</a> - Global professional association of specialists, clinicians and researchers
</li>
<li><a href="https://www.meaction.net/" target="_blank" rel="noreferrer noopener">ME Action</a> - patient-led action group founded in the USA
</li>
<li><a href="https://www.emerge.org.au/?gclid=CjwKCAjwnZaVBhA6EiwAVVyv9KP3OlN6vSmV3Ad0btyod49Ah8aOjPocKXXeGqrUQ7opitSxqpulaRoClTMQAvD_BwE" target="_blank" rel="noreferrer noopener">Emerge Australia</a> - one of several ME charities in Australia, free GP training modules
</li>
<li><a href="https://www.emerge.org.au/?gclid=CjwKCAjwnZaVBhA6EiwAVVyv9KP3OlN6vSmV3Ad0btyod49Ah8aOjPocKXXeGqrUQ7opitSxqpulaRoClTMQAvD_BwE" target="_blank" rel="noreferrer noopener">Physios for ME</a> - resources on post-exertional neuroimmune exhaustion (PENE/PEM)
</li>
</ul>
<div><br />
</div>
<div><strong>Italian language:</strong>
</div>
<ul>
<li>ME/CFS: <a href="https://associazionemara.org//pdf/Malattie/CFSME_MANUALE_PER_LA_PRATICA_CLINICA_2014_IACFS%2525252525252520_ITA.pdf" target="_blank" rel="noreferrer noopener">Un Manuale per la Pratica Clinica</a> - PDF
</li>
</ul>
<div><br />
</div>
<div><strong>Watch a documentary and researcher interviews:</strong>
</div>
<ul>
<li>ME/CFS “<a href="https://www.dialogues-mecfs.co.uk/videos/" target="_blank" rel="noreferrer noopener">Dialogues</a> ” film series online
</li>
<li>“<a href="https://www.unrest.film/" target="_blank" rel="noreferrer noopener">Unrest</a>  ” Sundance award-winning documentary on Netflix
</li>
<li>Prof. Resia Pretorius: Microcirculation, microclots in PASC and ME/CFS - <a href="https://www.youtube.com/watch?v=BZoNhDYciQk" target="_blank" rel="noreferrer noopener">YouTube 2024</a> 
</li>
</ul>
<div><br />
</div>
<div><strong>More on Microclots</strong>
</div>
<ul>
<li><a href="https://open.spotify.com/episode/5FSjgZH5JOWzkWabW3wh3q?si=2304d8e16cda4f85&amp;nd=1" target="_blank" rel="noreferrer noopener">Leading researchers on Microclots</a>  - Long-Covid Podcast, Spotify
</li>
<li><a href="https://cardiab.biomedcentral.com/articles/10.1186/s12933-021-01359-7" target="_blank" rel="noreferrer noopener">Persistent clotting protein pathology in Long COVI</a> D - 2021
</li>
<li>A <a href="https://www.thieme-connect.com/products/ejournals/pdf/10.1055/s-0043-1774796.pdf" target="_blank" rel="noreferrer noopener">Perspective on How Fibrinaloid Microclots</a> and Platelet Pathology May be Applied in Clinical Investigations - 2023
</li>
<li><a href="https://www.mdpi.com/2075-4426/14/2/170" target="_blank" rel="noreferrer noopener">Possible Role of Fibrinaloid Microclots in Postura</a>l Orthostatic Tachycardia Syndrome (POTS): Focus on Long COVID - 2024
</li>
<li><a href="https://www.mdpi.com/1424-8247/15/8/931#:~:text=The%2520platelet%2520populations%2520from%2520participants,1.00%2520(activation%2520with%2520pseudopodia)." target="_blank" rel="noreferrer noopener">The Occurrence of Hyperactivated Platelets</a>  and Fibrinaloid Microclots in Myalgic Encephalomyelitis - 2022
</li>
</ul>

Angelina Nguyen

Robbie Kentley

Elizabeth Finkel

Anonymous

Lumen Gorrie

Andrew Wilson

Beth Hendrix

Barry Kohn

Charles Adams

Carly Kenneally

Nick Sciola

Jessica Christiansen

Deborah Warren

Maria Crocker

Andrea Anthony

Jeremy Moore

Help Eliza Access New Critical Apheresis Treatment

platform

Platform is iOS

Android

Adyen Google Pay Development Audience

$opt_dummy_attribute

English only

Deprecate Stripe Legacy

dyn_template_ids

Adyen V6 Bene Transfer & MyMoney Campaign Organizers - test01

Bene transfer V6 and AdyenV6MyMoney Campaign Organizers - production

OneTrust next-app audience

fundCountryCode

NextDoor Share Option Users

Fundraisers with Reactions feature capability

fundCurrencyCode

US + Non-charity COs Only

locale

fund country is US and user language is English

personId

comms-internal-person-ids

Enhanced Story Experience Users

Suggested Goal Experience Users

user language is English and fund country: US, AU, DK, FI, IE, NO, SE, CA, GB; 

Poster share - new funds eligible (newest 9/18)

Streaming widgets beta user

paymentProcessor

3DS payment method

user language is English and fundCountry: US, AU, DK, FI, IE, NO, SE, CA, GB; 

currencyCode

Money Box Donation List Prompt Experiment Audience

GoFundMe Employees

ipAddress

Mark Rieth IP Address

Version 9.2.0 and above

Fund is in English speaking country

desktop

Android v12.11.0 and above

Platform is Android

paymentMethodType

checkoutType

Payment method type group to be vaulted on success

admin pr kit prod

EUR Donation Upsell

Share Text generation Skip Fundraiser

(prod) new funds eligible for amp12 (UGC gallery)

fintrac_cad_idv_form_v2 audience

paymentProcessorAccountId

fallback mode accounts

proCampaignId

p2p legacy startfundraising page

AMP24 New Funds Only PROD (DO NOT MODIFY)

countryCode

charityId

UKCharities

Federated Search Internal Testing

route.pathname community

US Donation Upsell audience 

Auto Thanks Feature Audience

Supporter Comments Eligible Funds

International Only

fundId

braze fundraiser group 

Payment Identity Transfers ATO Risk Check (Targeted) - Production

Fundraiser Saved Payment Method Rate Limit Bypass (Production)

leaderboard-partner-id-audience-givepanel

Version 9.2.1 and above

AUD Donation Upsell audience

fundraiserCountryCode is US/EN

Active Fundraiser - Smart Default Cadence

DAF Internal

Vault on success card payment method

Platform is iOS v11.0.0 and above

Desktop users

Person ids

United States (US) users

allow yuno fundraisers for test

Mexico country code

Posters INTL

NPO Profile Opted-In

iOS at or above 12.4.0

non-US recurring donors

Canada Campaign Owner Group

Fundraiser Without Meta Link

Scheduler payment tester gorup

charityCommunityId

Charities allow to be claimed unclaimed (PRD)

Canada (CA) users

UC Tipping v20250115 International

pymk_production_xplr_fe_team

Android at or above 12.2.0

Profile photo entry point audience

smart goals (fundraiser/manage) on test01

Activity Tracking v1 Beta Testing

start gfm intl allowed locales

Platform is iOS v11.2.0 and above

NPO upsell education category

unclaimed charities

prod_ach_audience

AI Chatbot Audience

amp13 only new funds (prod) (anyword auto)

UC Flow Enabled (Prod)

Payment Identity Beneficiary Verification - Production

shared notification bell audience

Custom users

ach frontend audience

Android v11.0.0 and above

Users Receiving Payments Paused Notifications

smart goals test01

Manage Coach - US English Organizers Only + new funds only

Team EGG - IP Address list

NPO recommendations prod

Fundraiser Without Instagram Deep Link

Native 11.4.0 and above

UC Tipping v20250107

Users Receiving Braze KYC Validation Failed

Native 11.3.0 and above

ai_title_page

anyword

openai

control

manual_entry

userEmail

template_id

userId

fundUrl

isCharityCo

email

appVersion

shouldBucketIntoExperiment

partnerId

donationCadence

isActiveFundraiser

isPartner

isMobile

npoProfileOptIn

fundIsLinkedWithMeta

hasSessionDonation

categoryGroup

isCampaignOwner

fundHasInstagramDeepLink

Native 11.4.0 and higher

New funds eligible - Video Sharing (PROD)

GB Donation Upsell audience 

Auto Thanks V3 Rollout Audience

Thank you V3 testing whitelist

isRecurringFriendly

Is Recurring Friendly

Excluded funds - Video Sharing

NPO upsell animals category

NPO upsell disaster relief category

Logged In Users

CH Donation Upsell audience

Android v10.6.0 and above

NPO upsell essential needs category

NPO upsell medical category

userCurrencyCode

Localized Currency

NPO upsell cancer category

v11.5.0 and above

testAudience

pathname

Survicate

appVersion is at or above 12.8.0

Non-charity fund

isChallengeFundraiser

challenge-fundraisers

Payment Identity Launch Verification - Production

New funds eligible - Posters v2

CAD Donation Upsell Audience

Braze Email Tester

NPO Profile Opted-Out

iOS App Version

hasKnownDonors

PYMK has donors

iOS v12.3.0 and above

Help Eliza Access New Critical Apheresis Treatment

Still $14,907 to go. Help us build momentum.